Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). This expanded indication marks a significant milestone, building on ILUMYA’s existing approval for plaque psoriasis and strengthening Sun Pharma’s position in the autoimmune disease market. The approval was based on positive results from the Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies.
Sun Pharma Secures Key FDA Approval for ILUMYA®
Sun Pharmaceutical Industries Limited announced a significant development in its innovative medicines portfolio with the U.S. Food and Drug Administration (FDA) approving ILUMYA® (tildrakizumab-asmn). This approval grants ILUMYA® a new indication for the treatment of adults suffering from active psoriatic arthritis (PsA). This marks a pivotal moment for Sun Pharma, as it expands the therapeutic reach of ILUMYA® beyond its established use in moderate-to-severe plaque psoriasis.
Expanding Treatment Options for Psoriatic Arthritis
The approval of ILUMYA® for active psoriatic arthritis is particularly noteworthy as it is an IL-23 inhibitor approved exclusively for healthcare provider-administered treatment. This offers a new therapeutic option for the approximately 2.4 million Americans living with psoriatic arthritis, a complex and chronic disease that can lead to permanent joint damage. Sun Pharma highlighted that this expanded use builds on the established clinical experience of ILUMYA® and provides patients with an option for regular in-office care, especially beneficial for those unable to self-administer treatment or who may benefit from clinician oversight.
Clinical Study Support and Product Profile
The FDA’s decision was supported by robust data from the Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. These global, multicenter, randomized, double-blind, placebo-controlled studies evaluated the efficacy and safety of tildrakizumab 100 mg in adults with active psoriatic arthritis. ILUMYA® is a humanized IgG1/k monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. This mechanism reduces the release of pro-inflammatory cytokines and chemokines. ILUMYA® is indicated in the United States for both moderate-to-severe plaque psoriasis and active psoriatic arthritis in adults. The drug has also received approvals for plaque psoriasis in several other countries including India, Australia, Canada, China, and Japan, and is marketed as ILUMETRI® in Europe.
Important Safety Information
The press release also included essential safety information regarding ILUMYA®. The common adverse reactions associated with ILUMYA® treatment for Plaque Psoriasis (≥1%) include upper respiratory infections, injection site reactions, and diarrhea. For Psoriatic Arthritis (≥3%), common adverse reactions include upper respiratory tract infections and COVID-19. Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment, and ILUMYA® is contraindicated in patients with a history of serious hypersensitivity reactions. The company also advises caution regarding potential increased risk of infection and recommends completion of age-appropriate immunizations prior to initiating therapy.
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is described as the world’s leading specialty generics company, with a diverse portfolio spanning innovative medicines, generics, and consumer healthcare products. It holds the position of the largest pharmaceutical company in India and is a prominent generic company in the U.S. and global Emerging Markets. The company’s high-growth global Innovative Medicines portfolio, which includes products in dermatology, ophthalmology, and onco-dermatology, contributes approximately 20% of its sales. Sun Pharma operates vertically integrated facilities across six continents, ensuring the delivery of high-quality medicines to over 100 countries.
Source: BSE
